{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Ara-290",
    "short_name": "ARA-290",
    "aliases": [
      "ara",
      "cibinetide"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what ARA-290 is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how ARA-290 appears in clinical literature, regulatory contexts, and real-world use. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "ARA-290 is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols",
        "tendon and ligament recovery support",
        "soft tissue healing after overuse or injury",
        "return-to-training support during rehab",
        "joint comfort and mobility support",
        "interest in tissue repair pathways"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for ARA-290",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_injury_healing",
        "topic_immune_modulation"
      ]
    },
    "slug": "ara-290"
  },
  "canonical_name": "Ara-290",
  "interactions": {
    "drug_classes": [
      "immune-modulation-infection-risk",
      "corticosteroids",
      "immunosuppressants"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "ARA-290 is discussed for nerve pain and inflammatory conditions based on early research directions. Human evidence is limited, so benefits are uncertain.",
    "benefits": [
      "neuropathic pain and nerve irritation interest (early-stage)",
      "inflammation-related symptom interest in some communities (anecdotal)",
      "sometimes discussed for small-fiber neuropathy contexts (evidence varies)"
    ],
    "side_effects_common": [
      "headache",
      "fatigue",
      "nausea"
    ],
    "side_effects_serious": [
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)",
      "severe dizziness, fainting, or confusion"
    ],
    "who_should_be_cautious": [
      "people with autoimmune disease on immunomodulating medications",
      "people with complex neurologic conditions requiring close medical supervision",
      "pregnant or breastfeeding individuals",
      "adolescents (limited evidence and long-term uncertainty)"
    ],
    "schema_version": "practical_block_v1"
  }
}
